 [1m([0morchestrator-hospitalization-LABETALOL[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDoes LABETALOL increase or decrease the risk of hospitalization?[0m
 [1m([0morchestrator-hospitalization-LABETALOL[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-hospitalization-LABETALOL[1m)[0m [31m Entity.AGENT [0m
*[1m([0morchestrator-hospitalization-LABETALOL[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mrecipient_message[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"recipient_message"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"intended_recipient"[0m[32m: [0m[32m"FDAHandler"[0m[32m,[0m
[32m    [0m[32m"content"[0m[32m: [0m[32m"Does LABETALOL increase or decrease the risk of hospitalization?"[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0morchestrator-hospitalization-LABETALOL[1m)[0m [37m Entity.AGENT [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [32mDoes LABETALOL increase or decrease the risk of hospitalization?[0m
 [1m([0morchestrator-hospitalization-LABETALOL[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-hospitalization-LABETALOL[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
 [1m([0morchestrator-hospitalization-LABETALOL[1m)[0m [31m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0mEntity.LLM[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m[[0m[32mCANNOT RESPOND[0m[1;32m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDoes LABETALOL increase or decrease the risk of hospitalization?[0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mrelevant_search_extracts[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"relevant_search_extracts"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"query"[0m[32m: [0m[32m"Does LABETALOL increase or decrease the risk of hospitalization?"[0m[32m,[0m
[32m    [0m[32m"drug"[0m[32m: [0m[32m"labetalol"[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mrelevant_search_extracts[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m 
[31m        Below are some relevant extracts for your query:[0m
[31m        -----[0m
[31m        [0m
[31mCONTENT: LABETALOL: adverse_reactions: ADVERSE REACTIONS Most adverse effects are mild and transient and occur early in the course of treatment. In controlled clinical trials of [0m[1;31m3[0m[31m to [0m[1;31m4[0m[31m months' [0m
[31mduration, discontinuation of labetalol hydrochloride tablets due to one or more adverse effects was required in [0m[1;31m7[0m[31m% of all patients. In these same trials, other agents with solely beta-blocking [0m
[31mactivity used in the control groups led to discontinuation in [0m[1;31m8[0m[31m% to [0m[1;31m10[0m[31m% of patients, and a centrally acting alpha-agonist led to discontinuation in [0m[1;31m30[0m[31m% of patients. The incidence rates of adverse [0m
[31mreactions listed in the following table were derived from multicenter, controlled clinical trials comparing labetalol HCl, placebo, metoprolol, and propranolol over treatment periods of [0m[1;31m3[0m[31m and [0m[1;31m4[0m[31m [0m
[31mmonths. Where the frequency of adverse effects for labetalol HCl and placebo is similar, causal relationship is uncertain. The rates are based on adverse reactions considered probably drug related by [0m
[31mthe investigator. LABETALOL: adverse_reactions: If all reports are considered, the rates are somewhat higher [0m[1;31m([0m[31me.g., dizziness, [0m[1;31m20[0m[31m%; nausea, [0m[1;31m14[0m[31m%; fatigue, [0m[1;31m11[0m[31m%[0m[1;31m)[0m[31m, but the overall conclusions are [0m
[31munchanged. LABETALOL: adverse_reactions: Labetalol HCI Placebo Propranolol Metoprolol [0m[1;31m([0m[31mn = [0m[1;31m227[0m[1;31m)[0m[31m [0m[1;31m([0m[31mn = [0m[1;31m98[0m[1;31m)[0m[31m [0m[1;31m([0m[31mn = [0m[1;31m84[0m[1;31m)[0m[31m [0m[1;31m([0m[31mn = [0m[1;31m49[0m[1;31m)[0m[31m % % % % Body as a whole Fatigue [0m[1;31m5[0m[31m [0m[1;31m0[0m[31m [0m[1;31m12[0m[31m [0m[1;31m12[0m[31m Asthenia [0m[1;31m1[0m[31m [0m[1;31m1[0m[31m [0m[1;31m1[0m[31m [0m[1;31m0[0m[31m Headache [0m[1;31m2[0m[31m [0m[1;31m1[0m[31m [0m[1;31m1[0m[31m [0m[1;31m2[0m[31m [0m
[31mGastrointestinal Nausea [0m[1;31m6[0m[31m [0m[1;31m1[0m[31m [0m[1;31m1[0m[31m [0m[1;31m2[0m[31m Vomiting <[0m[1;31m1[0m[31m [0m[1;31m0[0m[31m [0m[1;31m0[0m[31m [0m[1;31m0[0m[31m Dyspepsia [0m[1;31m3[0m[31m [0m[1;31m1[0m[31m [0m[1;31m1[0m[31m [0m[1;31m0[0m[31m Abdominal pain [0m[1;31m0[0m[31m [0m[1;31m0[0m[31m [0m[1;31m1[0m[31m [0m[1;31m2[0m[31m Diarrhea <[0m[1;31m1[0m[31m [0m[1;31m0[0m[31m [0m[1;31m2[0m[31m [0m[1;31m0[0m[31m Taste distortion [0m[1;31m1[0m[31m [0m[1;31m0[0m[31m [0m[1;31m0[0m[31m [0m[1;31m0[0m[31m Central and peripheral nervous systems Dizziness [0m[1;31m11[0m[31m [0m[1;31m3[0m[31m [0m[1;31m4[0m[31m [0m[1;31m4[0m[31m [0m
[31mParesthesia <[0m[1;31m1[0m[31m [0m[1;31m0[0m[31m [0m[1;31m0[0m[31m [0m[1;31m0[0m[31m Drowsiness <[0m[1;31m1[0m[31m [0m[1;31m2[0m[31m [0m[1;31m2[0m[31m [0m[1;31m2[0m[31m Autonomic nervous system Nasal stuffiness [0m[1;31m3[0m[31m [0m[1;31m0[0m[31m [0m[1;31m0[0m[31m LABETALOL: adverse_reactions: [0m[1;31m0[0m[31m Ejaculation failure [0m[1;31m2[0m[31m [0m[1;31m0[0m[31m [0m[1;31m0[0m[31m [0m[1;31m0[0m[31m Impotence [0m[1;31m1[0m[31m [0m[1;31m0[0m[31m [0m[1;31m1[0m[31m [0m[1;31m3[0m[31m Increased sweating <[0m[1;31m1[0m[31m [0m[1;31m0[0m[31m [0m[1;31m0[0m[31m [0m[1;31m0[0m[31m [0m
[31mCardiovascular Edema [0m[1;31m1[0m[31m [0m[1;31m0[0m[31m [0m[1;31m0[0m[31m [0m[1;31m0[0m[31m Postural hypotension [0m[1;31m1[0m[31m [0m[1;31m0[0m[31m [0m[1;31m0[0m[31m [0m[1;31m0[0m[31m Bradycardia [0m[1;31m0[0m[31m [0m[1;31m0[0m[31m [0m[1;31m5[0m[31m [0m[1;31m12[0m[31m Respiratory Dyspnea [0m[1;31m2[0m[31m [0m[1;31m0[0m[31m [0m[1;31m1[0m[31m [0m[1;31m2[0m[31m Skin Rash [0m[1;31m1[0m[31m [0m[1;31m0[0m[31m [0m[1;31m0[0m[31m [0m[1;31m0[0m[31m Special senses Visionabnormality [0m[1;31m1[0m[31m [0m[1;31m0[0m[31m [0m[1;31m0[0m[31m [0m[1;31m0[0m[31m Vertigo [0m[1;31m2[0m[31m [0m[1;31m1[0m[31m [0m[1;31m0[0m[31m [0m[1;31m0[0m[31m The adverse [0m
[31meffects were reported spontaneously and are representative of the incidence of adverse effects that may be observed in a properly selected hypertensive patient population, i.e., a group excluding [0m
[31mpatients with bronchospastic disease, overt congestive heart failure, or other contraindications to beta-blocker therapy. Clinical trials also included studies utilizing daily doses up to [0m[1;31m2[0m[31m,[0m[1;31m400[0m[31m mg in [0m
[31mmore severely hypertensive patients. LABETALOL: adverse_reactions: Certain of the side effects increased with increasing dose, as shown in the following table that depicts the entire U.S. therapeutic [0m
[31mtrials data base for adverse reactions that are clearly or possibly dose related. LABETALOL: adverse_reactions: Labetalol HCl Daily Dose [0m[1;31m([0m[31mmg[0m[1;31m)[0m[31m [0m[1;31m200[0m[31m [0m[1;31m300[0m[31m [0m[1;31m400[0m[31m [0m[1;31m600[0m[31m [0m[1;31m800[0m[31m [0m[1;31m900[0m[31m [0m[1;31m1[0m[31m,[0m[1;31m200[0m[31m [0m[1;31m1[0m[31m,[0m[1;31m600[0m[31m [0m[1;31m2[0m[31m,[0m[1;31m400[0m[31m Number of [0m
[31mpatients [0m[1;31m522[0m[31m [0m[1;31m181[0m[31m [0m[1;31m606[0m[31m [0m[1;31m608[0m[31m [0m[1;31m503[0m[31m [0m[1;31m117[0m[31m [0m[1;31m411[0m[31m [0m[1;31m242[0m[31m [0m[1;31m175[0m[31m Dizziness [0m[1;31m([0m[31m%[0m[1;31m)[0m[31m [0m[1;31m2[0m[31m [0m[1;31m3[0m[31m [0m[1;31m3[0m[31m [0m[1;31m3[0m[31m [0m[1;31m5[0m[31m [0m[1;31m1[0m[31m [0m[1;31m9[0m[31m [0m[1;31m13[0m[31m [0m[1;31m16[0m[31m Fatigue [0m[1;31m2[0m[31m [0m[1;31m1[0m[31m [0m[1;31m4[0m[31m [0m[1;31m4[0m[31m [0m[1;31m5[0m[31m [0m[1;31m3[0m[31m [0m[1;31m7[0m[31m [0m[1;31m6[0m[31m [0m[1;31m10[0m[31m Nausea <[0m[1;31m1[0m[31m [0m[1;31m0[0m[31m [0m[1;31m1[0m[31m [0m[1;31m2[0m[31m [0m[1;31m4[0m[31m [0m[1;31m0[0m[31m [0m[1;31m7[0m[31m [0m[1;31m11[0m[31m [0m[1;31m19[0m[31m Vomiting [0m[1;31m0[0m[31m [0m[1;31m0[0m[31m <[0m[1;31m1[0m[31m <[0m[1;31m1[0m[31m <[0m[1;31m1[0m[31m [0m[1;31m0[0m[31m [0m[1;31m1[0m[31m [0m[1;31m2[0m[31m [0m[1;31m3[0m[31m Dyspepsia [0m[1;31m1[0m[31m [0m[1;31m0[0m[31m [0m[1;31m2[0m[31m [0m[1;31m1[0m[31m [0m[1;31m1[0m[31m [0m[1;31m0[0m[31m [0m[1;31m2[0m[31m [0m[1;31m2[0m[31m [0m[1;31m4[0m[31m [0m
[31mParesthesia [0m[1;31m2[0m[31m [0m[1;31m0[0m[31m [0m[1;31m2[0m[31m [0m[1;31m2[0m[31m [0m[1;31m1[0m[31m [0m[1;31m1[0m[31m [0m[1;31m2[0m[31m [0m[1;31m5[0m[31m [0m[1;31m5[0m[31m Nasal stuffiness [0m[1;31m1[0m[31m [0m[1;31m1[0m[31m [0m[1;31m2[0m[31m [0m[1;31m2[0m[31m [0m[1;31m2[0m[31m [0m[1;31m2[0m[31m LABETALOL: adverse_reactions: [0m[1;31m4[0m[31m [0m[1;31m5[0m[31m [0m[1;31m6[0m[31m Ejaculation failure [0m[1;31m0[0m[31m [0m[1;31m2[0m[31m [0m[1;31m1[0m[31m [0m[1;31m2[0m[31m [0m[1;31m3[0m[31m [0m[1;31m0[0m[31m [0m[1;31m4[0m[31m [0m[1;31m3[0m[31m [0m[1;31m5[0m[31m Impotence [0m[1;31m1[0m[31m [0m[1;31m1[0m[31m [0m[1;31m1[0m[31m [0m[1;31m1[0m[31m [0m[1;31m2[0m[31m [0m[1;31m4[0m[31m [0m[1;31m3[0m[31m [0m[1;31m4[0m[31m [0m[1;31m3[0m[31m Edema [0m[1;31m1[0m[31m [0m[1;31m0[0m[31m [0m[1;31m1[0m[31m [0m[1;31m1[0m[31m [0m[1;31m1[0m[31m [0m[1;31m0[0m[31m [0m[1;31m1[0m[31m [0m[1;31m2[0m[31m [0m[1;31m2[0m[31m In addition, a [0m
[31mnumber of other less common adverse events have been reported: Body as a Whole: Fever. Cardiovascular: Hypotension, and rarely, syncope, bradycardia, heart block. Central and Peripheral Nervous [0m
[31mSystems: Paresthesia, most frequently described as scalp tingling. In most cases, it was mild and transient and usually occurred at the beginning of treatment. Collagen Disorders: Systemic lupus [0m
[31merythematosus, positive antinuclear factor. Eyes: Dry eyes. Immunological System: Antimitochondrial antibodies.         [0m
[31mSOURCE:LABETALOL label[0m


[31mCONTENT: LABETALOL: labor_and_delivery: Labor & Delivery Labetalol HCl given to pregnant women with hypertension did not appear to affect the usual course of labor and delivery.         [0m
[31mSOURCE:LABETALOL label[0m


[31mCONTENT: LABETALOL: drug_interactions: Drug Interactions In one survey, [0m[1;31m2.3[0m[31m% of patients taking labetalol HCl in combination with tricyclic antidepressants experienced tremor, as compared to [0m[1;31m0.7[0m[31m% [0m
[31mreported to occur with labetalol HCl alone. The contribution of each of the treatments to this adverse reaction is unknown, but the possibility of a drug interaction cannot be excluded. Drugs [0m
[31mpossessing beta-blocking properties can blunt the bronchodilator effect of beta-receptor agonist drugs in patients with bronchospasm; therefore, doses greater than the normal antiasthmatic dose of [0m
[31mbeta-agonist bronchodilator drugs may be required. Cimetidine has been shown to increase the bioavailability of labetalol HCl. Since this could be explained either by enhanced absorption or by an [0m
[31malteration of hepatic metabolism of labetalol HCl, special care should be used in establishing the dose required for blood pressure control in such patients. LABETALOL: drug_interactions: Synergism [0m
[31mhas been shown between halothane anesthesia and intravenously administered labetalol HCl. During controlled hypotensive anesthesia using labetalol HCl in association with halothane, high [0m
[31mconcentrations [0m[1;31m([0m[1;31m3[0m[31m% or above[0m[1;31m)[0m[31m of halothane should not be used because the degree of hypotension will be increased and because of the possibility of a large reduction in cardiac output and an increase [0m
[31min central venous pressure. The anesthesiologist should be informed when a patient is receiving labetalol HCl. Labetalol HCl blunts the reflex tachycardia produced by nitroglycerin without preventing [0m
[31mits hypotensive effect. If labetalol HCl is used with nitroglycerin in patients with angina pectoris, additional antihypertensive effects may occur. Care should be taken if labetalol is used [0m
[31mconcomitantly with calcium antagonists of the verapamil type. LABETALOL: drug_interactions: Both digitalis glycosides and beta-blockers slow atrioventricular conduction and decrease heart [0m
[31mrate.Concomitant use can increase the risk of bradycardia. Risk of Anaphylactic Reaction: While taking beta-blockers, patients with a history of severe anaphylactic reaction to a variety of allergens [0m
[31mmay be more reactive to repeated challenge, either accidental, diagnostic, or therapeutic. Such patients may be unresponsive to the usual doses of epinephrine used to treat allergic reaction.         [0m
[31mSOURCE:LABETALOL label[0m


[31mCONTENT: LABETALOL: pregnancy: Pregnancy Teratogenic Effects: Pregnancy Category C: Teratogenic studies were performed with labetalol in rats and rabbits at oral doses up to approximately six and four[0m
[31mtimes the maximum recommended human dose [0m[1;31m([0m[31mMRHD[0m[1;31m)[0m[31m, respectively. No reproducible evidence of fetal malformations was observed. Increased fetal resorptions were seen in both species at doses [0m
[31mapproximating the MRHD. A teratology study performed with labetalol in rabbits at IV doses up to [0m[1;31m1.7[0m[31m times the MRHD revealed no evidence of drug related harm to the fetus. There are no adequate and [0m
[31mwell-controlled studies in pregnant women. Labetalol should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Nonteratogenic Effects: Hypotension, [0m
[31mbradycardia, hypoglycemia, and respiratory depression have been reported in infants of mothers who were treated with labetalol HCl for hypertension during pregnancy. LABETALOL: pregnancy: Oral [0m
[31madministration of labetalol to rats during late gestation through weaning at doses of two to four times the MRHD caused a decrease in neonatal survival.         [0m
[31mSOURCE:LABETALOL label[0m


[31mCONTENT: LABETALOL: adverse_reactions: Liver and Biliary System: Hepatic necrosis, hepatitis, cholestatic jaundice, elevated liver function tests. Musculoskeletal System: Muscle cramps, toxic [0m
[31mmyopathy. Respiratory System: Bronchospasm. Skin and Appendages: Rashes of various types, such as generalized maculopapular, lichenoid, urticarial, bullous lichen planus, psoriaform, and facial [0m
[31merythema; Peyronie's disease; reversible alopecia. Urinary System: Difficulty in micturition, including acute urinary bladder retention. Hypersensitivity: Rare reports of hypersensitivity [0m[1;31m([0m[31me.g., rash,[0m
[31murticaria, pruritus, angioedema, dyspnea[0m[1;31m)[0m[31m and anaphylactoid reactions. Following approval for marketing in the United Kingdom, a monitored release survey involving approximately [0m[1;31m6[0m[31m,[0m[1;31m800[0m[31m patients was [0m
[31mconducted for further safety and efficacy evaluation of this product. LABETALOL: adverse_reactions: Results of this survey indicate that the type, severity, and incidence of adverse effects were [0m
[31mcomparable to those cited above. Potential Adverse Effects: In addition, other adverse effects not listed above have been reported with other beta-adrenergic blocking agents. Central Nervous System: [0m
[31mReversible mental depression progressing to catatonia, an acute reversible syndrome characterized by disorientation for time and place, short-term memory loss, emotional lability, slightly clouded [0m
[31msensorium, and decreased performance on psychometrics. Cardiovascular: Intensification of A-V block [0m[1;31m([0m[31msee CONTRAINDICATIONS [0m[1;31m)[0m[31m. Allergic: Fever combined with aching and sore throat, laryngospasm, [0m
[31mrespiratory distress. Hematologic: Agranulocytosis, thrombocytopenic or nonthrombocytopenic purpura. Gastrointestinal: Mesenteric artery thrombosis, ischemic colitis. LABETALOL: adverse_reactions: The[0m
[31moculomucocutaneous syndrome associated with the beta-blocker practolol has not been reported with labetalol HCl. Clinical Laboratory Tests: There have been reversible increases of serum transaminases [0m
[31min [0m[1;31m4[0m[31m% of patients treated with labetalol HCl and tested and, more rarely, reversible increases in blood urea.         [0m
[31mSOURCE:LABETALOL label[0m


[31mCONTENT: LABETALOL: openfda: spl_id         [0m
[31mSOURCE:LABETALOL label[0m


[31mCONTENT: LABETALOL: precautions: Also, transient scalp tingling may occur, usually when treatment with labetalol hydrochloride tabletsis initiated [0m[1;31m([0m[31msee ADVERSE REACTIONS [0m[1;31m)[0m[31m. Laboratory Tests As with [0m
[31many new drug given over prolonged periods, laboratory parameters should be observed over regular intervals. In patients with concomitant illnesses, such as impaired renal function, appropriate tests [0m
[31mshould be done to monitor these conditions. Drug Interactions In one survey, [0m[1;31m2.3[0m[31m% of patients taking labetalol HCl in combination with tricyclic antidepressants experienced tremor, as compared to [0m[1;31m0.7[0m[31m%[0m
[31mreported to occur with labetalol HCl alone. The contribution of each of the treatments to this adverse reaction is unknown, but the possibility of a drug interaction cannot be excluded. LABETALOL: [0m
[31mprecautions: Drugs possessing beta-blocking properties can blunt the bronchodilator effect of beta-receptor agonist drugs in patients with bronchospasm; therefore, doses greater than the normal [0m
[31mantiasthmatic dose of beta-agonist bronchodilator drugs may be required. Cimetidine has been shown to increase the bioavailability of labetalol HCl. Since this could be explained either by enhanced [0m
[31mabsorption or by an alteration of hepatic metabolism of labetalol HCl, special care should be used in establishing the dose required for blood pressure control in such patients. Synergism has been [0m
[31mshown between halothane anesthesia and intravenously administered labetalol HCl. LABETALOL: precautions: During controlled hypotensive anesthesia using labetalol HCl in association with halothane, [0m
[31mhigh concentrations [0m[1;31m([0m[1;31m3[0m[31m% or above[0m[1;31m)[0m[31m of halothane should not be used because the degree of hypotension will be increased and because of the possibility of a large reduction in cardiac output and an [0m
[31mincrease in central venous pressure. The anesthesiologist should be informed when a patient is receiving labetalol HCl. Labetalol HCl blunts the reflex tachycardia produced by nitroglycerin without [0m
[31mpreventing its hypotensive effect. If labetalol HCl is used with nitroglycerin in patients with angina pectoris, additional antihypertensive effects may occur. Care should be taken if labetalol is [0m
[31mused concomitantly with calcium antagonists of the verapamil type. Both digitalis glycosides and beta-blockers slow atrioventricular conduction and decrease heart rate. LABETALOL: precautions: [0m
[31mcomitant use can increase the risk of bradycardia. Risk of Anaphylactic Reaction: While taking beta-blockers, patients with a history of severe anaphylactic reaction to a variety of allergens may be [0m
[31mmore reactive to repeated challenge, either accidental, diagnostic, or therapeutic. Such patients may be unresponsive to the usual doses of epinephrine used to treat allergic reaction. Drug & OR [0m
[31mLaboratory Test Interactions The presence of labetalol metabolites in the urine may result in falsely elevated levels of urinary catecholamines, metanephrine, normetanephrine, and vanillylmandelic [0m
[31macid when measured by fluorimetric or photometric methods. In screening patients suspected of having a pheochromocytoma and being treated with labetalol HCl, a specific method, such as a high [0m
[31mperformance liquid chromatographic assay with solid phase extraction [0m[1;31m([0m[31me.g. LABETALOL: precautions: J Chromatogr [0m[1;31m385:241[0m[31m,[0m[1;31m1987[0m[1;31m)[0m[31m should be employed in determining levels of catecholamines. Labetalol HCl [0m
[31mhas also been reported to produce a false-positive test for amphetamine when screening urine for the presence of drugs using the commercially available assay methods Toxi-Lab A Â® [0m[1;31m([0m[31mthin-layer [0m
[31mchromatographic assay[0m[1;31m)[0m[31m and Emit-d.a.u Â® [0m[1;31m([0m[31mradioenzymatic assay[0m[1;31m)[0m[31m. When patients being treated with labetalol have a positive urine test for amphetamine using these techniques, confirmation should be [0m
[31mmade by using more specific methods, such as a gas chromatographic-mass spectrometer technique. Carcinogenesis & Mutagenesis & Impairment Of Fertility Long-term oral dosing studies with labetalol HCl [0m
[31mfor [0m[1;31m18[0m[31m months in mice and for [0m[1;31m2[0m[31m years in rats showed no evidence of carcinogenesis.         [0m
[31mSOURCE:LABETALOL label[0m


[31mCONTENT: LABETALOL: clinical_pharmacology: Hemodynamic effects are variable, with small, nonsignificant changes in cardiac output seen in some studies but not others, and small decreases in total [0m
[31mperipheral resistance. Elevated plasma renins are reduced. Doses of labetalol HCl that controlled hypertension did not affect renal function in mildly to severely hypertensive patients with normal [0m
[31mrenal function. Due to the alpha [0m[1;31m1[0m[31m -receptor blocking activity of labetalol HCl, blood pressure is lowered more in the standing than in the supine position, and symptoms of postural hypotension [0m[1;31m([0m[1;31m2[0m[31m%[0m[1;31m)[0m[31m, [0m
[31mincluding rare instances of syncope, can occur. Following oral administration, when postural hypotension has occurred, it has been transient and is uncommon when the recommended starting dose and [0m
[31mtitration increments are closely followed [0m[1;31m([0m[31msee DOSAGE AND ADMINISTRATION [0m[1;31m)[0m[31m. Symptomatic postural hypotension is most likely to occur [0m[1;31m2[0m[31m to [0m[1;31m4[0m[31m hours after a dose, especially following the use of large [0m
[31minitial doses or upon large changes in dose. LABETALOL: clinical_pharmacology: The peak effects of single oral doses of labetalol HCl occur within [0m[1;31m2[0m[31m to [0m[1;31m4[0m[31m hours. The duration of effect depends upon [0m
[31mdose, lasting at least [0m[1;31m8[0m[31m hours following single oral doses of [0m[1;31m100[0m[31m mg and more than [0m[1;31m12[0m[31m hours following single oral doses of [0m[1;31m300[0m[31m mg. The maximum, steady-state blood pressure response upon oral, [0m
[31mtwice-a-day dosing occurs within [0m[1;31m24[0m[31m to [0m[1;31m72[0m[31m hours. The antihypertensive effect of labetalol has a linear correlation with the logarithm of labetalol plasma concentration, and there is also a linear [0m
[31mcorrelation between the reduction in exercise-induced tachycardia occurring at [0m[1;31m2[0m[31m hours after oral administration of labetalol HCl and the logarithm of the plasma concentration. About [0m[1;31m70[0m[31m% of the [0m
[31mmaximum beta-blocking effect is present for [0m[1;31m5[0m[31m hours after the administration of a single oral dose of [0m[1;31m400[0m[31m mg with suggestion that about [0m[1;31m40[0m[31m% remains at [0m[1;31m8[0m[31m hours. LABETALOL: clinical_pharmacology: The [0m
[31mantianginal efficacy of labetalol HCl has not been studied. In [0m[1;31m37[0m[31m patients with hypertension and coronary artery disease, labetalol HCl did not increase the incidence or severity of angina attacks. [0m
[31mExacerbation of angina and, in some cases, myocardial infarction and ventricular dysrhythmias have been reported after abrupt discontinuation of therapy with beta-adrenergic blocking agents in [0m
[31mpatients with coronary artery disease. Abrupt withdrawal of these agents in patients without coronary artery disease has resulted in transient symptoms, including tremulousness, sweating, palpitation,[0m
[31mheadache, and malaise. Several mechanisms have been proposed to explain these phenomena, among them increased sensitivity to catecholamines because of increased numbers of beta receptors. Although [0m
[31mbeta-adrenergic receptor blockade is useful in the treatment of angina and hypertension, there are also situations in which sympathetic stimulation is vital. LABETALOL: clinical_pharmacology: For [0m
[31mexample, in patients with severely damaged hearts, adequate ventricular function may depend on sympathetic drive. Beta-adrenergic blockade may worsen A-V block by preventing the necessary facilitating[0m
[31meffects of sympathetic activity on conduction. Beta [0m[1;31m2[0m[31m -adrenergic blockade results in passive bronchial constriction by interfering with endogenous adrenergic bronchodilator activity in patients [0m
[31msubject to bronchospasm, and it may also interfere with exogenous bronchodilators in such patients. Pharmacokinetics and Metabolism: Labetalol HCl is completely absorbed from the gastrointestinal [0m
[31mtract with peak plasma levels occurring [0m[1;31m1[0m[31m to [0m[1;31m2[0m[31m hours after oral administration. The relative bioavailability of labetalol HCl tablets compared to an oral solution is [0m[1;31m100[0m[31m%. The absolute bioavailability[0m
[1;31m([0m[31mfraction of drug reaching systemic circulation[0m[1;31m)[0m[31m of labetalol when compared to an IV infusion is [0m[1;31m25[0m[31m%; this is due to extensive [0m[31m"first-pass"[0m[31m metabolism. LABETALOL: clinical_pharmacology: Despite [0m
[31m"first-pass"[0m[31m metabolism, there is a linear relationship between oral doses of [0m[1;31m100[0m[31m to [0m[1;31m3[0m[31m,[0m[1;31m000[0m[31m mg and peak plasma levels. The absolute bioavailability of labetalol is increased when administered with [0m
[31mfood. The plasma half-life of labetalol following oral administration is about [0m[1;31m6[0m[31m to [0m[1;31m8[0m[31m hours. Steady-state plasma levels of labetalol during repetitive dosing are reached by about the third day of [0m
[31mdosing. In patients with decreased hepatic or renal function, the elimination half-life of labetalol is not altered; however, the relative bioavailability in hepatically impaired patients is increased[0m
[31mdue to decreased [0m[31m"first-pass"[0m[31m metabolism. The metabolism of labetalol is mainly through conjugation to glucuronide metabolites. These metabolites are present in plasma and are excreted in the urine [0m
[31mand, via the bile, into the feces.         [0m
[31mSOURCE:LABETALOL label[0m


[31mCONTENT: LABETALOL: laboratory_tests: Laboratory Tests As with any new drug given over prolonged periods, laboratory parameters should be observed over regular intervals. In patients with concomitant [0m
[31millnesses, such as impaired renal function, appropriate tests should be done to monitor these conditions.         [0m
[31mSOURCE:LABETALOL label[0m

[31m        -----[0m
[31m        If NONE of the extracts are relevant, try doing a web search with the[0m
[31m        `relevant_search_extracts` tool/function-call[0m
[31m        [0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [32m DO-NOT-KNOW[0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDO-NOT-KNOW[0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mrelevant_search_extracts[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"relevant_search_extracts"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"query"[0m[32m: [0m[32m"Does LABETALOL increase or decrease the risk of hospitalization?"[0m[32m,[0m
[32m    [0m[32m"drug"[0m[32m: [0m[32m"labetalol"[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mrelevant_search_extracts[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [31mNo relevant extracts found for Does LABETALOL increase or decrease the risk of [0m
[31mhospitalization?[0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m<[0m[1;32mDONE[0m[1;32m>[0m[32m DO-NOT-KNOW[0m
 [1m([0morchestrator-hospitalization-LABETALOL[1m)[0m [31m FDAHandler [0m [1;34mEntity.USER[0m[1m([0mFDAHandler[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDO-NOT-KNOW[0m
 [1m([0morchestrator-hospitalization-LABETALOL[1m)[0m [31m Critic [0m [1;34mEntity.USER[0m[1m([0m    Critic[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
*[1m([0morchestrator-hospitalization-LABETALOL[1m)[0m [37m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDO-NOT-KNOW[0m
 [1m([0morchestrator-hospitalization-LABETALOL[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-hospitalization-LABETALOL[1m)[0m [31m Entity.AGENT [0m
*[1m([0morchestrator-hospitalization-LABETALOL[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mrecipient_message[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"recipient_message"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"intended_recipient"[0m[32m: [0m[32m"FDAHandler"[0m[32m,[0m
[32m    [0m[32m"content"[0m[32m: [0m[32m"Does LABETALOL increase or decrease the risk of hospitalization?"[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0morchestrator-hospitalization-LABETALOL[1m)[0m [37m Entity.AGENT [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [32mDoes LABETALOL increase or decrease the risk of hospitalization?[0m
 [1m([0morchestrator-hospitalization-LABETALOL[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-hospitalization-LABETALOL[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
 [1m([0morchestrator-hospitalization-LABETALOL[1m)[0m [31m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0mEntity.LLM[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m[[0m[32mCANNOT RESPOND[0m[1;32m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDoes LABETALOL increase or decrease the risk of hospitalization?[0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mrelevant_search_extracts[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"relevant_search_extracts"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"query"[0m[32m: [0m[32m"Does LABETALOL increase or decrease the risk of hospitalization?"[0m[32m,[0m
[32m    [0m[32m"drug"[0m[32m: [0m[32m"labetalol"[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mrelevant_search_extracts[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m 
[31mCONTENT: LABETALOL: adverse_reactions: ADVERSE REACTIONS Most adverse effects are mild and transient and occur early in the course of treatment. In controlled clinical trials of [0m[1;31m3[0m[31m to [0m[1;31m4[0m[31m months' [0m
[31mduration, discontinuation of labetalol hydrochloride tablets due to one or more adverse effects was required in [0m[1;31m7[0m[31m% of all patients. In these same trials, other agents with solely beta-blocking [0m
[31mactivity used in the control groups led to discontinuation in [0m[1;31m8[0m[31m% to [0m[1;31m10[0m[31m% of patients, and a centrally acting alpha-agonist led to discontinuation in [0m[1;31m30[0m[31m% of patients. The incidence rates of adverse [0m
[31mreactions listed in the following table were derived from multicenter, controlled clinical trials comparing labetalol HCl, placebo, metoprolol, and propranolol over treatment periods of [0m[1;31m3[0m[31m and [0m[1;31m4[0m[31m [0m
[31mmonths. Where the frequency of adverse effects for labetalol HCl and placebo is similar, causal relationship is uncertain. The rates are based on adverse reactions considered probably drug related by [0m
[31mthe investigator. LABETALOL: adverse_reactions: If all reports are considered, the rates are somewhat higher [0m[1;31m([0m[31me.g., dizziness, [0m[1;31m20[0m[31m%; nausea, [0m[1;31m14[0m[31m%; fatigue, [0m[1;31m11[0m[31m%[0m[1;31m)[0m[31m, but the overall conclusions are [0m
[31munchanged. LABETALOL: adverse_reactions: Labetalol HCI Placebo Propranolol Metoprolol [0m[1;31m([0m[31mn = [0m[1;31m227[0m[1;31m)[0m[31m [0m[1;31m([0m[31mn = [0m[1;31m98[0m[1;31m)[0m[31m [0m[1;31m([0m[31mn = [0m[1;31m84[0m[1;31m)[0m[31m [0m[1;31m([0m[31mn = [0m[1;31m49[0m[1;31m)[0m[31m % % % % Body as a whole Fatigue [0m[1;31m5[0m[31m [0m[1;31m0[0m[31m [0m[1;31m12[0m[31m [0m[1;31m12[0m[31m Asthenia [0m[1;31m1[0m[31m [0m[1;31m1[0m[31m [0m[1;31m1[0m[31m [0m[1;31m0[0m[31m Headache [0m[1;31m2[0m[31m [0m[1;31m1[0m[31m [0m[1;31m1[0m[31m [0m[1;31m2[0m[31m [0m
[31mGastrointestinal Nausea [0m[1;31m6[0m[31m [0m[1;31m1[0m[31m [0m[1;31m1[0m[31m [0m[1;31m2[0m[31m Vomiting <[0m[1;31m1[0m[31m [0m[1;31m0[0m[31m [0m[1;31m0[0m[31m [0m[1;31m0[0m[31m Dyspepsia [0m[1;31m3[0m[31m [0m[1;31m1[0m[31m [0m[1;31m1[0m[31m [0m[1;31m0[0m[31m Abdominal pain [0m[1;31m0[0m[31m [0m[1;31m0[0m[31m [0m[1;31m1[0m[31m [0m[1;31m2[0m[31m Diarrhea <[0m[1;31m1[0m[31m [0m[1;31m0[0m[31m [0m[1;31m2[0m[31m [0m[1;31m0[0m[31m Taste distortion [0m[1;31m1[0m[31m [0m[1;31m0[0m[31m [0m[1;31m0[0m[31m [0m[1;31m0[0m[31m Central and peripheral nervous systems Dizziness [0m[1;31m11[0m[31m [0m[1;31m3[0m[31m [0m[1;31m4[0m[31m [0m[1;31m4[0m[31m [0m
[31mParesthesia <[0m[1;31m1[0m[31m [0m[1;31m0[0m[31m [0m[1;31m0[0m[31m [0m[1;31m0[0m[31m Drowsiness <[0m[1;31m1[0m[31m [0m[1;31m2[0m[31m [0m[1;31m2[0m[31m [0m[1;31m2[0m[31m Autonomic nervous system Nasal stuffiness [0m[1;31m3[0m[31m [0m[1;31m0[0m[31m [0m[1;31m0[0m[31m LABETALOL: adverse_reactions: [0m[1;31m0[0m[31m Ejaculation failure [0m[1;31m2[0m[31m [0m[1;31m0[0m[31m [0m[1;31m0[0m[31m [0m[1;31m0[0m[31m Impotence [0m[1;31m1[0m[31m [0m[1;31m0[0m[31m [0m[1;31m1[0m[31m [0m[1;31m3[0m[31m Increased sweating <[0m[1;31m1[0m[31m [0m[1;31m0[0m[31m [0m[1;31m0[0m[31m [0m[1;31m0[0m[31m [0m
[31mCardiovascular Edema [0m[1;31m1[0m[31m [0m[1;31m0[0m[31m [0m[1;31m0[0m[31m [0m[1;31m0[0m[31m Postural hypotension [0m[1;31m1[0m[31m [0m[1;31m0[0m[31m [0m[1;31m0[0m[31m [0m[1;31m0[0m[31m Bradycardia [0m[1;31m0[0m[31m [0m[1;31m0[0m[31m [0m[1;31m5[0m[31m [0m[1;31m12[0m[31m Respiratory Dyspnea [0m[1;31m2[0m[31m [0m[1;31m0[0m[31m [0m[1;31m1[0m[31m [0m[1;31m2[0m[31m Skin Rash [0m[1;31m1[0m[31m [0m[1;31m0[0m[31m [0m[1;31m0[0m[31m [0m[1;31m0[0m[31m Special senses Visionabnormality [0m[1;31m1[0m[31m [0m[1;31m0[0m[31m [0m[1;31m0[0m[31m [0m[1;31m0[0m[31m Vertigo [0m[1;31m2[0m[31m [0m[1;31m1[0m[31m [0m[1;31m0[0m[31m [0m[1;31m0[0m[31m The adverse [0m
[31meffects were reported spontaneously and are representative of the incidence of adverse effects that may be observed in a properly selected hypertensive patient population, i.e., a group excluding [0m
[31mpatients with bronchospastic disease, overt congestive heart failure, or other contraindications to beta-blocker therapy. Clinical trials also included studies utilizing daily doses up to [0m[1;31m2[0m[31m,[0m[1;31m400[0m[31m mg in [0m
[31mmore severely hypertensive patients. LABETALOL: adverse_reactions: Certain of the side effects increased with increasing dose, as shown in the following table that depicts the entire U.S. therapeutic [0m
[31mtrials data base for adverse reactions that are clearly or possibly dose related. LABETALOL: adverse_reactions: Labetalol HCl Daily Dose [0m[1;31m([0m[31mmg[0m[1;31m)[0m[31m [0m[1;31m200[0m[31m [0m[1;31m300[0m[31m [0m[1;31m400[0m[31m [0m[1;31m600[0m[31m [0m[1;31m800[0m[31m [0m[1;31m900[0m[31m [0m[1;31m1[0m[31m,[0m[1;31m200[0m[31m [0m[1;31m1[0m[31m,[0m[1;31m600[0m[31m [0m[1;31m2[0m[31m,[0m[1;31m400[0m[31m Number of [0m
[31mpatients [0m[1;31m522[0m[31m [0m[1;31m181[0m[31m [0m[1;31m606[0m[31m [0m[1;31m608[0m[31m [0m[1;31m503[0m[31m [0m[1;31m117[0m[31m [0m[1;31m411[0m[31m [0m[1;31m242[0m[31m [0m[1;31m175[0m[31m Dizziness [0m[1;31m([0m[31m%[0m[1;31m)[0m[31m [0m[1;31m2[0m[31m [0m[1;31m3[0m[31m [0m[1;31m3[0m[31m [0m[1;31m3[0m[31m [0m[1;31m5[0m[31m [0m[1;31m1[0m[31m [0m[1;31m9[0m[31m [0m[1;31m13[0m[31m [0m[1;31m16[0m[31m Fatigue [0m[1;31m2[0m[31m [0m[1;31m1[0m[31m [0m[1;31m4[0m[31m [0m[1;31m4[0m[31m [0m[1;31m5[0m[31m [0m[1;31m3[0m[31m [0m[1;31m7[0m[31m [0m[1;31m6[0m[31m [0m[1;31m10[0m[31m Nausea <[0m[1;31m1[0m[31m [0m[1;31m0[0m[31m [0m[1;31m1[0m[31m [0m[1;31m2[0m[31m [0m[1;31m4[0m[31m [0m[1;31m0[0m[31m [0m[1;31m7[0m[31m [0m[1;31m11[0m[31m [0m[1;31m19[0m[31m Vomiting [0m[1;31m0[0m[31m [0m[1;31m0[0m[31m <[0m[1;31m1[0m[31m <[0m[1;31m1[0m[31m <[0m[1;31m1[0m[31m [0m[1;31m0[0m[31m [0m[1;31m1[0m[31m [0m[1;31m2[0m[31m [0m[1;31m3[0m[31m Dyspepsia [0m[1;31m1[0m[31m [0m[1;31m0[0m[31m [0m[1;31m2[0m[31m [0m[1;31m1[0m[31m [0m[1;31m1[0m[31m [0m[1;31m0[0m[31m [0m[1;31m2[0m[31m [0m[1;31m2[0m[31m [0m[1;31m4[0m[31m [0m
[31mParesthesia [0m[1;31m2[0m[31m [0m[1;31m0[0m[31m [0m[1;31m2[0m[31m [0m[1;31m2[0m[31m [0m[1;31m1[0m[31m [0m[1;31m1[0m[31m [0m[1;31m2[0m[31m [0m[1;31m5[0m[31m [0m[1;31m5[0m[31m Nasal stuffiness [0m[1;31m1[0m[31m [0m[1;31m1[0m[31m [0m[1;31m2[0m[31m [0m[1;31m2[0m[31m [0m[1;31m2[0m[31m [0m[1;31m2[0m[31m LABETALOL: adverse_reactions: [0m[1;31m4[0m[31m [0m[1;31m5[0m[31m [0m[1;31m6[0m[31m Ejaculation failure [0m[1;31m0[0m[31m [0m[1;31m2[0m[31m [0m[1;31m1[0m[31m [0m[1;31m2[0m[31m [0m[1;31m3[0m[31m [0m[1;31m0[0m[31m [0m[1;31m4[0m[31m [0m[1;31m3[0m[31m [0m[1;31m5[0m[31m Impotence [0m[1;31m1[0m[31m [0m[1;31m1[0m[31m [0m[1;31m1[0m[31m [0m[1;31m1[0m[31m [0m[1;31m2[0m[31m [0m[1;31m4[0m[31m [0m[1;31m3[0m[31m [0m[1;31m4[0m[31m [0m[1;31m3[0m[31m Edema [0m[1;31m1[0m[31m [0m[1;31m0[0m[31m [0m[1;31m1[0m[31m [0m[1;31m1[0m[31m [0m[1;31m1[0m[31m [0m[1;31m0[0m[31m [0m[1;31m1[0m[31m [0m[1;31m2[0m[31m [0m[1;31m2[0m[31m In addition, a [0m
[31mnumber of other less common adverse events have been reported: Body as a Whole: Fever. Cardiovascular: Hypotension, and rarely, syncope, bradycardia, heart block. Central and Peripheral Nervous [0m
[31mSystems: Paresthesia, most frequently described as scalp tingling. In most cases, it was mild and transient and usually occurred at the beginning of treatment. Collagen Disorders: Systemic lupus [0m
[31merythematosus, positive antinuclear factor. Eyes: Dry eyes. Immunological System: Antimitochondrial antibodies.         [0m
[31mSOURCE:LABETALOL label[0m


[31mCONTENT: LABETALOL: labor_and_delivery: Labor & Delivery Labetalol HCl given to pregnant women with hypertension did not appear to affect the usual course of labor and delivery.         [0m
[31mSOURCE:LABETALOL label[0m


[31mCONTENT: LABETALOL: drug_interactions: Drug Interactions In one survey, [0m[1;31m2.3[0m[31m% of patients taking labetalol HCl in combination with tricyclic antidepressants experienced tremor, as compared to [0m[1;31m0.7[0m[31m% [0m
[31mreported to occur with labetalol HCl alone. The contribution of each of the treatments to this adverse reaction is unknown, but the possibility of a drug interaction cannot be excluded. Drugs [0m
[31mpossessing beta-blocking properties can blunt the bronchodilator effect of beta-receptor agonist drugs in patients with bronchospasm; therefore, doses greater than the normal antiasthmatic dose of [0m
[31mbeta-agonist bronchodilator drugs may be required. Cimetidine has been shown to increase the bioavailability of labetalol HCl. Since this could be explained either by enhanced absorption or by an [0m
[31malteration of hepatic metabolism of labetalol HCl, special care should be used in establishing the dose required for blood pressure control in such patients. LABETALOL: drug_interactions: Synergism [0m
[31mhas been shown between halothane anesthesia and intravenously administered labetalol HCl. During controlled hypotensive anesthesia using labetalol HCl in association with halothane, high [0m
[31mconcentrations [0m[1;31m([0m[1;31m3[0m[31m% or above[0m[1;31m)[0m[31m of halothane should not be used because the degree of hypotension will be increased and because of the possibility of a large reduction in cardiac output and an increase [0m
[31min central venous pressure. The anesthesiologist should be informed when a patient is receiving labetalol HCl. Labetalol HCl blunts the reflex tachycardia produced by nitroglycerin without preventing [0m
[31mits hypotensive effect. If labetalol HCl is used with nitroglycerin in patients with angina pectoris, additional antihypertensive effects may occur. Care should be taken if labetalol is used [0m
[31mconcomitantly with calcium antagonists of the verapamil type. LABETALOL: drug_interactions: Both digitalis glycosides and beta-blockers slow atrioventricular conduction and decrease heart [0m
[31mrate.Concomitant use can increase the risk of bradycardia. Risk of Anaphylactic Reaction: While taking beta-blockers, patients with a history of severe anaphylactic reaction to a variety of allergens [0m
[31mmay be more reactive to repeated challenge, either accidental, diagnostic, or therapeutic. Such patients may be unresponsive to the usual doses of epinephrine used to treat allergic reaction.         [0m
[31mSOURCE:LABETALOL label[0m


[31mCONTENT: LABETALOL: pregnancy: Pregnancy Teratogenic Effects: Pregnancy Category C: Teratogenic studies were performed with labetalol in rats and rabbits at oral doses up to approximately six and four[0m
[31mtimes the maximum recommended human dose [0m[1;31m([0m[31mMRHD[0m[1;31m)[0m[31m, respectively. No reproducible evidence of fetal malformations was observed. Increased fetal resorptions were seen in both species at doses [0m
[31mapproximating the MRHD. A teratology study performed with labetalol in rabbits at IV doses up to [0m[1;31m1.7[0m[31m times the MRHD revealed no evidence of drug related harm to the fetus. There are no adequate and [0m
[31mwell-controlled studies in pregnant women. Labetalol should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Nonteratogenic Effects: Hypotension, [0m
[31mbradycardia, hypoglycemia, and respiratory depression have been reported in infants of mothers who were treated with labetalol HCl for hypertension during pregnancy. LABETALOL: pregnancy: Oral [0m
[31madministration of labetalol to rats during late gestation through weaning at doses of two to four times the MRHD caused a decrease in neonatal survival.         [0m
[31mSOURCE:LABETALOL label[0m


[31mCONTENT: LABETALOL: adverse_reactions: Liver and Biliary System: Hepatic necrosis, hepatitis, cholestatic jaundice, elevated liver function tests. Musculoskeletal System: Muscle cramps, toxic [0m
[31mmyopathy. Respiratory System: Bronchospasm. Skin and Appendages: Rashes of various types, such as generalized maculopapular, lichenoid, urticarial, bullous lichen planus, psoriaform, and facial [0m
[31merythema; Peyronie's disease; reversible alopecia. Urinary System: Difficulty in micturition, including acute urinary bladder retention. Hypersensitivity: Rare reports of hypersensitivity [0m[1;31m([0m[31me.g., rash,[0m
[31murticaria, pruritus, angioedema, dyspnea[0m[1;31m)[0m[31m and anaphylactoid reactions. Following approval for marketing in the United Kingdom, a monitored release survey involving approximately [0m[1;31m6[0m[31m,[0m[1;31m800[0m[31m patients was [0m
[31mconducted for further safety and efficacy evaluation of this product. LABETALOL: adverse_reactions: Results of this survey indicate that the type, severity, and incidence of adverse effects were [0m
[31mcomparable to those cited above. Potential Adverse Effects: In addition, other adverse effects not listed above have been reported with other beta-adrenergic blocking agents. Central Nervous System: [0m
[31mReversible mental depression progressing to catatonia, an acute reversible syndrome characterized by disorientation for time and place, short-term memory loss, emotional lability, slightly clouded [0m
[31msensorium, and decreased performance on psychometrics. Cardiovascular: Intensification of A-V block [0m[1;31m([0m[31msee CONTRAINDICATIONS [0m[1;31m)[0m[31m. Allergic: Fever combined with aching and sore throat, laryngospasm, [0m
[31mrespiratory distress. Hematologic: Agranulocytosis, thrombocytopenic or nonthrombocytopenic purpura. Gastrointestinal: Mesenteric artery thrombosis, ischemic colitis. LABETALOL: adverse_reactions: The[0m
[31moculomucocutaneous syndrome associated with the beta-blocker practolol has not been reported with labetalol HCl. Clinical Laboratory Tests: There have been reversible increases of serum transaminases [0m
[31min [0m[1;31m4[0m[31m% of patients treated with labetalol HCl and tested and, more rarely, reversible increases in blood urea.         [0m
[31mSOURCE:LABETALOL label[0m


[31mCONTENT: LABETALOL: openfda: spl_id         [0m
[31mSOURCE:LABETALOL label[0m


[31mCONTENT: LABETALOL: precautions: Also, transient scalp tingling may occur, usually when treatment with labetalol hydrochloride tabletsis initiated [0m[1;31m([0m[31msee ADVERSE REACTIONS [0m[1;31m)[0m[31m. Laboratory Tests As with [0m
[31many new drug given over prolonged periods, laboratory parameters should be observed over regular intervals. In patients with concomitant illnesses, such as impaired renal function, appropriate tests [0m
[31mshould be done to monitor these conditions. Drug Interactions In one survey, [0m[1;31m2.3[0m[31m% of patients taking labetalol HCl in combination with tricyclic antidepressants experienced tremor, as compared to [0m[1;31m0.7[0m[31m%[0m
[31mreported to occur with labetalol HCl alone. The contribution of each of the treatments to this adverse reaction is unknown, but the possibility of a drug interaction cannot be excluded. LABETALOL: [0m
[31mprecautions: Drugs possessing beta-blocking properties can blunt the bronchodilator effect of beta-receptor agonist drugs in patients with bronchospasm; therefore, doses greater than the normal [0m
[31mantiasthmatic dose of beta-agonist bronchodilator drugs may be required. Cimetidine has been shown to increase the bioavailability of labetalol HCl. Since this could be explained either by enhanced [0m
[31mabsorption or by an alteration of hepatic metabolism of labetalol HCl, special care should be used in establishing the dose required for blood pressure control in such patients. Synergism has been [0m
[31mshown between halothane anesthesia and intravenously administered labetalol HCl. LABETALOL: precautions: During controlled hypotensive anesthesia using labetalol HCl in association with halothane, [0m
[31mhigh concentrations [0m[1;31m([0m[1;31m3[0m[31m% or above[0m[1;31m)[0m[31m of halothane should not be used because the degree of hypotension will be increased and because of the possibility of a large reduction in cardiac output and an [0m
[31mincrease in central venous pressure. The anesthesiologist should be informed when a patient is receiving labetalol HCl. Labetalol HCl blunts the reflex tachycardia produced by nitroglycerin without [0m
[31mpreventing its hypotensive effect. If labetalol HCl is used with nitroglycerin in patients with angina pectoris, additional antihypertensive effects may occur. Care should be taken if labetalol is [0m
[31mused concomitantly with calcium antagonists of the verapamil type. Both digitalis glycosides and beta-blockers slow atrioventricular conduction and decrease heart rate. LABETALOL: precautions: [0m
[31mcomitant use can increase the risk of bradycardia. Risk of Anaphylactic Reaction: While taking beta-blockers, patients with a history of severe anaphylactic reaction to a variety of allergens may be [0m
[31mmore reactive to repeated challenge, either accidental, diagnostic, or therapeutic. Such patients may be unresponsive to the usual doses of epinephrine used to treat allergic reaction. Drug & OR [0m
[31mLaboratory Test Interactions The presence of labetalol metabolites in the urine may result in falsely elevated levels of urinary catecholamines, metanephrine, normetanephrine, and vanillylmandelic [0m
[31macid when measured by fluorimetric or photometric methods. In screening patients suspected of having a pheochromocytoma and being treated with labetalol HCl, a specific method, such as a high [0m
[31mperformance liquid chromatographic assay with solid phase extraction [0m[1;31m([0m[31me.g. LABETALOL: precautions: J Chromatogr [0m[1;31m385:241[0m[31m,[0m[1;31m1987[0m[1;31m)[0m[31m should be employed in determining levels of catecholamines. Labetalol HCl [0m
[31mhas also been reported to produce a false-positive test for amphetamine when screening urine for the presence of drugs using the commercially available assay methods Toxi-Lab A Â® [0m[1;31m([0m[31mthin-layer [0m
[31mchromatographic assay[0m[1;31m)[0m[31m and Emit-d.a.u Â® [0m[1;31m([0m[31mradioenzymatic assay[0m[1;31m)[0m[31m. When patients being treated with labetalol have a positive urine test for amphetamine using these techniques, confirmation should be [0m
[31mmade by using more specific methods, such as a gas chromatographic-mass spectrometer technique. Carcinogenesis & Mutagenesis & Impairment Of Fertility Long-term oral dosing studies with labetalol HCl [0m
[31mfor [0m[1;31m18[0m[31m months in mice and for [0m[1;31m2[0m[31m years in rats showed no evidence of carcinogenesis.         [0m
[31mSOURCE:LABETALOL label[0m


[31mCONTENT: LABETALOL: clinical_pharmacology: Hemodynamic effects are variable, with small, nonsignificant changes in cardiac output seen in some studies but not others, and small decreases in total [0m
[31mperipheral resistance. Elevated plasma renins are reduced. Doses of labetalol HCl that controlled hypertension did not affect renal function in mildly to severely hypertensive patients with normal [0m
[31mrenal function. Due to the alpha [0m[1;31m1[0m[31m -receptor blocking activity of labetalol HCl, blood pressure is lowered more in the standing than in the supine position, and symptoms of postural hypotension [0m[1;31m([0m[1;31m2[0m[31m%[0m[1;31m)[0m[31m, [0m
[31mincluding rare instances of syncope, can occur. Following oral administration, when postural hypotension has occurred, it has been transient and is uncommon when the recommended starting dose and [0m
[31mtitration increments are closely followed [0m[1;31m([0m[31msee DOSAGE AND ADMINISTRATION [0m[1;31m)[0m[31m. Symptomatic postural hypotension is most likely to occur [0m[1;31m2[0m[31m to [0m[1;31m4[0m[31m hours after a dose, especially following the use of large [0m
[31minitial doses or upon large changes in dose. LABETALOL: clinical_pharmacology: The peak effects of single oral doses of labetalol HCl occur within [0m[1;31m2[0m[31m to [0m[1;31m4[0m[31m hours. The duration of effect depends upon [0m
[31mdose, lasting at least [0m[1;31m8[0m[31m hours following single oral doses of [0m[1;31m100[0m[31m mg and more than [0m[1;31m12[0m[31m hours following single oral doses of [0m[1;31m300[0m[31m mg. The maximum, steady-state blood pressure response upon oral, [0m
[31mtwice-a-day dosing occurs within [0m[1;31m24[0m[31m to [0m[1;31m72[0m[31m hours. The antihypertensive effect of labetalol has a linear correlation with the logarithm of labetalol plasma concentration, and there is also a linear [0m
[31mcorrelation between the reduction in exercise-induced tachycardia occurring at [0m[1;31m2[0m[31m hours after oral administration of labetalol HCl and the logarithm of the plasma concentration. About [0m[1;31m70[0m[31m% of the [0m
[31mmaximum beta-blocking effect is present for [0m[1;31m5[0m[31m hours after the administration of a single oral dose of [0m[1;31m400[0m[31m mg with suggestion that about [0m[1;31m40[0m[31m% remains at [0m[1;31m8[0m[31m hours. LABETALOL: clinical_pharmacology: The [0m
[31mantianginal efficacy of labetalol HCl has not been studied. In [0m[1;31m37[0m[31m patients with hypertension and coronary artery disease, labetalol HCl did not increase the incidence or severity of angina attacks. [0m
[31mExacerbation of angina and, in some cases, myocardial infarction and ventricular dysrhythmias have been reported after abrupt discontinuation of therapy with beta-adrenergic blocking agents in [0m
[31mpatients with coronary artery disease. Abrupt withdrawal of these agents in patients without coronary artery disease has resulted in transient symptoms, including tremulousness, sweating, palpitation,[0m
[31mheadache, and malaise. Several mechanisms have been proposed to explain these phenomena, among them increased sensitivity to catecholamines because of increased numbers of beta receptors. Although [0m
[31mbeta-adrenergic receptor blockade is useful in the treatment of angina and hypertension, there are also situations in which sympathetic stimulation is vital. LABETALOL: clinical_pharmacology: For [0m
[31mexample, in patients with severely damaged hearts, adequate ventricular function may depend on sympathetic drive. Beta-adrenergic blockade may worsen A-V block by preventing the necessary facilitating[0m
[31meffects of sympathetic activity on conduction. Beta [0m[1;31m2[0m[31m -adrenergic blockade results in passive bronchial constriction by interfering with endogenous adrenergic bronchodilator activity in patients [0m
[31msubject to bronchospasm, and it may also interfere with exogenous bronchodilators in such patients. Pharmacokinetics and Metabolism: Labetalol HCl is completely absorbed from the gastrointestinal [0m
[31mtract with peak plasma levels occurring [0m[1;31m1[0m[31m to [0m[1;31m2[0m[31m hours after oral administration. The relative bioavailability of labetalol HCl tablets compared to an oral solution is [0m[1;31m100[0m[31m%. The absolute bioavailability[0m
[1;31m([0m[31mfraction of drug reaching systemic circulation[0m[1;31m)[0m[31m of labetalol when compared to an IV infusion is [0m[1;31m25[0m[31m%; this is due to extensive [0m[31m"first-pass"[0m[31m metabolism. LABETALOL: clinical_pharmacology: Despite [0m
[31m"first-pass"[0m[31m metabolism, there is a linear relationship between oral doses of [0m[1;31m100[0m[31m to [0m[1;31m3[0m[31m,[0m[1;31m000[0m[31m mg and peak plasma levels. The absolute bioavailability of labetalol is increased when administered with [0m
[31mfood. The plasma half-life of labetalol following oral administration is about [0m[1;31m6[0m[31m to [0m[1;31m8[0m[31m hours. Steady-state plasma levels of labetalol during repetitive dosing are reached by about the third day of [0m
[31mdosing. In patients with decreased hepatic or renal function, the elimination half-life of labetalol is not altered; however, the relative bioavailability in hepatically impaired patients is increased[0m
[31mdue to decreased [0m[31m"first-pass"[0m[31m metabolism. The metabolism of labetalol is mainly through conjugation to glucuronide metabolites. These metabolites are present in plasma and are excreted in the urine [0m
[31mand, via the bile, into the feces.         [0m
[31mSOURCE:LABETALOL label[0m


[31mCONTENT: LABETALOL: laboratory_tests: Laboratory Tests As with any new drug given over prolonged periods, laboratory parameters should be observed over regular intervals. In patients with concomitant [0m
[31millnesses, such as impaired renal function, appropriate tests should be done to monitor these conditions.         [0m
[31mSOURCE:LABETALOL label[0m

 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m<[0m[1;32mDONE[0m[1;32m>[0m[32m DO-NOT-KNOW[0m
 [1m([0morchestrator-hospitalization-LABETALOL[1m)[0m [31m FDAHandler [0m [1;34mEntity.USER[0m[1m([0mFDAHandler[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDO-NOT-KNOW[0m
 [1m([0morchestrator-hospitalization-LABETALOL[1m)[0m [31m Critic [0m [1;34mEntity.USER[0m[1m([0m    Critic[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
*[1m([0morchestrator-hospitalization-LABETALOL[1m)[0m [37m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDO-NOT-KNOW[0m
 [1m([0morchestrator-hospitalization-LABETALOL[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-hospitalization-LABETALOL[1m)[0m [31m Entity.AGENT [0m
*[1m([0morchestrator-hospitalization-LABETALOL[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mrecipient_message[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"recipient_message"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"intended_recipient"[0m[32m: [0m[32m"FDAHandler"[0m[32m,[0m
[32m    [0m[32m"content"[0m[32m: [0m[32m"Does LABETALOL increase or decrease the risk of hospitalization?"[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0morchestrator-hospitalization-LABETALOL[1m)[0m [37m Entity.AGENT [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [32mDoes LABETALOL increase or decrease the risk of hospitalization?[0m
 [1m([0morchestrator-hospitalization-LABETALOL[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-hospitalization-LABETALOL[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
 [1m([0morchestrator-hospitalization-LABETALOL[1m)[0m [31m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0mEntity.LLM[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m[[0m[32mCANNOT RESPOND[0m[1;32m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDoes LABETALOL increase or decrease the risk of hospitalization?[0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mrelevant_search_extracts[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"relevant_search_extracts"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"query"[0m[32m: [0m[32m"Does LABETALOL increase or decrease the risk of hospitalization?"[0m[32m,[0m
[32m    [0m[32m"drug"[0m[32m: [0m[32m"labetalol"[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mrelevant_search_extracts[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [31mNo relevant extracts found for Does LABETALOL increase or decrease the risk of [0m
[31mhospitalization?[0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m<[0m[1;32mDONE[0m[1;32m>[0m[32m DO-NOT-KNOW[0m
 [1m([0morchestrator-hospitalization-LABETALOL[1m)[0m [31m FDAHandler [0m [1;34mEntity.USER[0m[1m([0mFDAHandler[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDO-NOT-KNOW[0m
 [1m([0morchestrator-hospitalization-LABETALOL[1m)[0m [31m Critic [0m [1;34mEntity.USER[0m[1m([0m    Critic[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
*[1m([0morchestrator-hospitalization-LABETALOL[1m)[0m [37m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDO-NOT-KNOW[0m
 [1m([0morchestrator-hospitalization-LABETALOL[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-hospitalization-LABETALOL[1m)[0m [31m Entity.AGENT [0m
*[1m([0morchestrator-hospitalization-LABETALOL[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mrecipient_message[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"recipient_message"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"intended_recipient"[0m[32m: [0m[32m"FDAHandler"[0m[32m,[0m
[32m    [0m[32m"content"[0m[32m: [0m[32m"Does LABETALOL increase or decrease the risk of hospitalization?"[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0morchestrator-hospitalization-LABETALOL[1m)[0m [37m Entity.AGENT [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [32mDoes LABETALOL increase or decrease the risk of hospitalization?[0m
 [1m([0morchestrator-hospitalization-LABETALOL[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-hospitalization-LABETALOL[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
 [1m([0morchestrator-hospitalization-LABETALOL[1m)[0m [31m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0mEntity.LLM[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m[[0m[32mCANNOT RESPOND[0m[1;32m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDoes LABETALOL increase or decrease the risk of hospitalization?[0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mrelevant_search_extracts[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"relevant_search_extracts"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"query"[0m[32m: [0m[32m"Does LABETALOL increase or decrease the risk of hospitalization?"[0m[32m,[0m
[32m    [0m[32m"drug"[0m[32m: [0m[32m"labetalol"[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mrelevant_search_extracts[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m 
[31mCONTENT: LABETALOL: adverse_reactions: ADVERSE REACTIONS Most adverse effects are mild and transient and occur early in the course of treatment. In controlled clinical trials of [0m[1;31m3[0m[31m to [0m[1;31m4[0m[31m months' [0m
[31mduration, discontinuation of labetalol hydrochloride tablets due to one or more adverse effects was required in [0m[1;31m7[0m[31m% of all patients. In these same trials, other agents with solely beta-blocking [0m
[31mactivity used in the control groups led to discontinuation in [0m[1;31m8[0m[31m% to [0m[1;31m10[0m[31m% of patients, and a centrally acting alpha-agonist led to discontinuation in [0m[1;31m30[0m[31m% of patients. The incidence rates of adverse [0m
[31mreactions listed in the following table were derived from multicenter, controlled clinical trials comparing labetalol HCl, placebo, metoprolol, and propranolol over treatment periods of [0m[1;31m3[0m[31m and [0m[1;31m4[0m[31m [0m
[31mmonths. Where the frequency of adverse effects for labetalol HCl and placebo is similar, causal relationship is uncertain. The rates are based on adverse reactions considered probably drug related by [0m
[31mthe investigator. LABETALOL: adverse_reactions: If all reports are considered, the rates are somewhat higher [0m[1;31m([0m[31me.g., dizziness, [0m[1;31m20[0m[31m%; nausea, [0m[1;31m14[0m[31m%; fatigue, [0m[1;31m11[0m[31m%[0m[1;31m)[0m[31m, but the overall conclusions are [0m
[31munchanged. LABETALOL: adverse_reactions: Labetalol HCI Placebo Propranolol Metoprolol [0m[1;31m([0m[31mn = [0m[1;31m227[0m[1;31m)[0m[31m [0m[1;31m([0m[31mn = [0m[1;31m98[0m[1;31m)[0m[31m [0m[1;31m([0m[31mn = [0m[1;31m84[0m[1;31m)[0m[31m [0m[1;31m([0m[31mn = [0m[1;31m49[0m[1;31m)[0m[31m % % % % Body as a whole Fatigue [0m[1;31m5[0m[31m [0m[1;31m0[0m[31m [0m[1;31m12[0m[31m [0m[1;31m12[0m[31m Asthenia [0m[1;31m1[0m[31m [0m[1;31m1[0m[31m [0m[1;31m1[0m[31m [0m[1;31m0[0m[31m Headache [0m[1;31m2[0m[31m [0m[1;31m1[0m[31m [0m[1;31m1[0m[31m [0m[1;31m2[0m[31m [0m
[31mGastrointestinal Nausea [0m[1;31m6[0m[31m [0m[1;31m1[0m[31m [0m[1;31m1[0m[31m [0m[1;31m2[0m[31m Vomiting <[0m[1;31m1[0m[31m [0m[1;31m0[0m[31m [0m[1;31m0[0m[31m [0m[1;31m0[0m[31m Dyspepsia [0m[1;31m3[0m[31m [0m[1;31m1[0m[31m [0m[1;31m1[0m[31m [0m[1;31m0[0m[31m Abdominal pain [0m[1;31m0[0m[31m [0m[1;31m0[0m[31m [0m[1;31m1[0m[31m [0m[1;31m2[0m[31m Diarrhea <[0m[1;31m1[0m[31m [0m[1;31m0[0m[31m [0m[1;31m2[0m[31m [0m[1;31m0[0m[31m Taste distortion [0m[1;31m1[0m[31m [0m[1;31m0[0m[31m [0m[1;31m0[0m[31m [0m[1;31m0[0m[31m Central and peripheral nervous systems Dizziness [0m[1;31m11[0m[31m [0m[1;31m3[0m[31m [0m[1;31m4[0m[31m [0m[1;31m4[0m[31m [0m
[31mParesthesia <[0m[1;31m1[0m[31m [0m[1;31m0[0m[31m [0m[1;31m0[0m[31m [0m[1;31m0[0m[31m Drowsiness <[0m[1;31m1[0m[31m [0m[1;31m2[0m[31m [0m[1;31m2[0m[31m [0m[1;31m2[0m[31m Autonomic nervous system Nasal stuffiness [0m[1;31m3[0m[31m [0m[1;31m0[0m[31m [0m[1;31m0[0m[31m LABETALOL: adverse_reactions: [0m[1;31m0[0m[31m Ejaculation failure [0m[1;31m2[0m[31m [0m[1;31m0[0m[31m [0m[1;31m0[0m[31m [0m[1;31m0[0m[31m Impotence [0m[1;31m1[0m[31m [0m[1;31m0[0m[31m [0m[1;31m1[0m[31m [0m[1;31m3[0m[31m Increased sweating <[0m[1;31m1[0m[31m [0m[1;31m0[0m[31m [0m[1;31m0[0m[31m [0m[1;31m0[0m[31m [0m
[31mCardiovascular Edema [0m[1;31m1[0m[31m [0m[1;31m0[0m[31m [0m[1;31m0[0m[31m [0m[1;31m0[0m[31m Postural hypotension [0m[1;31m1[0m[31m [0m[1;31m0[0m[31m [0m[1;31m0[0m[31m [0m[1;31m0[0m[31m Bradycardia [0m[1;31m0[0m[31m [0m[1;31m0[0m[31m [0m[1;31m5[0m[31m [0m[1;31m12[0m[31m Respiratory Dyspnea [0m[1;31m2[0m[31m [0m[1;31m0[0m[31m [0m[1;31m1[0m[31m [0m[1;31m2[0m[31m Skin Rash [0m[1;31m1[0m[31m [0m[1;31m0[0m[31m [0m[1;31m0[0m[31m [0m[1;31m0[0m[31m Special senses Visionabnormality [0m[1;31m1[0m[31m [0m[1;31m0[0m[31m [0m[1;31m0[0m[31m [0m[1;31m0[0m[31m Vertigo [0m[1;31m2[0m[31m [0m[1;31m1[0m[31m [0m[1;31m0[0m[31m [0m[1;31m0[0m[31m The adverse [0m
[31meffects were reported spontaneously and are representative of the incidence of adverse effects that may be observed in a properly selected hypertensive patient population, i.e., a group excluding [0m
[31mpatients with bronchospastic disease, overt congestive heart failure, or other contraindications to beta-blocker therapy. Clinical trials also included studies utilizing daily doses up to [0m[1;31m2[0m[31m,[0m[1;31m400[0m[31m mg in [0m
[31mmore severely hypertensive patients. LABETALOL: adverse_reactions: Certain of the side effects increased with increasing dose, as shown in the following table that depicts the entire U.S. therapeutic [0m
[31mtrials data base for adverse reactions that are clearly or possibly dose related. LABETALOL: adverse_reactions: Labetalol HCl Daily Dose [0m[1;31m([0m[31mmg[0m[1;31m)[0m[31m [0m[1;31m200[0m[31m [0m[1;31m300[0m[31m [0m[1;31m400[0m[31m [0m[1;31m600[0m[31m [0m[1;31m800[0m[31m [0m[1;31m900[0m[31m [0m[1;31m1[0m[31m,[0m[1;31m200[0m[31m [0m[1;31m1[0m[31m,[0m[1;31m600[0m[31m [0m[1;31m2[0m[31m,[0m[1;31m400[0m[31m Number of [0m
[31mpatients [0m[1;31m522[0m[31m [0m[1;31m181[0m[31m [0m[1;31m606[0m[31m [0m[1;31m608[0m[31m [0m[1;31m503[0m[31m [0m[1;31m117[0m[31m [0m[1;31m411[0m[31m [0m[1;31m242[0m[31m [0m[1;31m175[0m[31m Dizziness [0m[1;31m([0m[31m%[0m[1;31m)[0m[31m [0m[1;31m2[0m[31m [0m[1;31m3[0m[31m [0m[1;31m3[0m[31m [0m[1;31m3[0m[31m [0m[1;31m5[0m[31m [0m[1;31m1[0m[31m [0m[1;31m9[0m[31m [0m[1;31m13[0m[31m [0m[1;31m16[0m[31m Fatigue [0m[1;31m2[0m[31m [0m[1;31m1[0m[31m [0m[1;31m4[0m[31m [0m[1;31m4[0m[31m [0m[1;31m5[0m[31m [0m[1;31m3[0m[31m [0m[1;31m7[0m[31m [0m[1;31m6[0m[31m [0m[1;31m10[0m[31m Nausea <[0m[1;31m1[0m[31m [0m[1;31m0[0m[31m [0m[1;31m1[0m[31m [0m[1;31m2[0m[31m [0m[1;31m4[0m[31m [0m[1;31m0[0m[31m [0m[1;31m7[0m[31m [0m[1;31m11[0m[31m [0m[1;31m19[0m[31m Vomiting [0m[1;31m0[0m[31m [0m[1;31m0[0m[31m <[0m[1;31m1[0m[31m <[0m[1;31m1[0m[31m <[0m[1;31m1[0m[31m [0m[1;31m0[0m[31m [0m[1;31m1[0m[31m [0m[1;31m2[0m[31m [0m[1;31m3[0m[31m Dyspepsia [0m[1;31m1[0m[31m [0m[1;31m0[0m[31m [0m[1;31m2[0m[31m [0m[1;31m1[0m[31m [0m[1;31m1[0m[31m [0m[1;31m0[0m[31m [0m[1;31m2[0m[31m [0m[1;31m2[0m[31m [0m[1;31m4[0m[31m [0m
[31mParesthesia [0m[1;31m2[0m[31m [0m[1;31m0[0m[31m [0m[1;31m2[0m[31m [0m[1;31m2[0m[31m [0m[1;31m1[0m[31m [0m[1;31m1[0m[31m [0m[1;31m2[0m[31m [0m[1;31m5[0m[31m [0m[1;31m5[0m[31m Nasal stuffiness [0m[1;31m1[0m[31m [0m[1;31m1[0m[31m [0m[1;31m2[0m[31m [0m[1;31m2[0m[31m [0m[1;31m2[0m[31m [0m[1;31m2[0m[31m LABETALOL: adverse_reactions: [0m[1;31m4[0m[31m [0m[1;31m5[0m[31m [0m[1;31m6[0m[31m Ejaculation failure [0m[1;31m0[0m[31m [0m[1;31m2[0m[31m [0m[1;31m1[0m[31m [0m[1;31m2[0m[31m [0m[1;31m3[0m[31m [0m[1;31m0[0m[31m [0m[1;31m4[0m[31m [0m[1;31m3[0m[31m [0m[1;31m5[0m[31m Impotence [0m[1;31m1[0m[31m [0m[1;31m1[0m[31m [0m[1;31m1[0m[31m [0m[1;31m1[0m[31m [0m[1;31m2[0m[31m [0m[1;31m4[0m[31m [0m[1;31m3[0m[31m [0m[1;31m4[0m[31m [0m[1;31m3[0m[31m Edema [0m[1;31m1[0m[31m [0m[1;31m0[0m[31m [0m[1;31m1[0m[31m [0m[1;31m1[0m[31m [0m[1;31m1[0m[31m [0m[1;31m0[0m[31m [0m[1;31m1[0m[31m [0m[1;31m2[0m[31m [0m[1;31m2[0m[31m In addition, a [0m
[31mnumber of other less common adverse events have been reported: Body as a Whole: Fever. Cardiovascular: Hypotension, and rarely, syncope, bradycardia, heart block. Central and Peripheral Nervous [0m
[31mSystems: Paresthesia, most frequently described as scalp tingling. In most cases, it was mild and transient and usually occurred at the beginning of treatment. Collagen Disorders: Systemic lupus [0m
[31merythematosus, positive antinuclear factor. Eyes: Dry eyes. Immunological System: Antimitochondrial antibodies.         [0m
[31mSOURCE:LABETALOL label[0m


[31mCONTENT: LABETALOL: labor_and_delivery: Labor & Delivery Labetalol HCl given to pregnant women with hypertension did not appear to affect the usual course of labor and delivery.         [0m
[31mSOURCE:LABETALOL label[0m


[31mCONTENT: LABETALOL: drug_interactions: Drug Interactions In one survey, [0m[1;31m2.3[0m[31m% of patients taking labetalol HCl in combination with tricyclic antidepressants experienced tremor, as compared to [0m[1;31m0.7[0m[31m% [0m
[31mreported to occur with labetalol HCl alone. The contribution of each of the treatments to this adverse reaction is unknown, but the possibility of a drug interaction cannot be excluded. Drugs [0m
[31mpossessing beta-blocking properties can blunt the bronchodilator effect of beta-receptor agonist drugs in patients with bronchospasm; therefore, doses greater than the normal antiasthmatic dose of [0m
[31mbeta-agonist bronchodilator drugs may be required. Cimetidine has been shown to increase the bioavailability of labetalol HCl. Since this could be explained either by enhanced absorption or by an [0m
[31malteration of hepatic metabolism of labetalol HCl, special care should be used in establishing the dose required for blood pressure control in such patients. LABETALOL: drug_interactions: Synergism [0m
[31mhas been shown between halothane anesthesia and intravenously administered labetalol HCl. During controlled hypotensive anesthesia using labetalol HCl in association with halothane, high [0m
[31mconcentrations [0m[1;31m([0m[1;31m3[0m[31m% or above[0m[1;31m)[0m[31m of halothane should not be used because the degree of hypotension will be increased and because of the possibility of a large reduction in cardiac output and an increase [0m
[31min central venous pressure. The anesthesiologist should be informed when a patient is receiving labetalol HCl. Labetalol HCl blunts the reflex tachycardia produced by nitroglycerin without preventing [0m
[31mits hypotensive effect. If labetalol HCl is used with nitroglycerin in patients with angina pectoris, additional antihypertensive effects may occur. Care should be taken if labetalol is used [0m
[31mconcomitantly with calcium antagonists of the verapamil type. LABETALOL: drug_interactions: Both digitalis glycosides and beta-blockers slow atrioventricular conduction and decrease heart [0m
[31mrate.Concomitant use can increase the risk of bradycardia. Risk of Anaphylactic Reaction: While taking beta-blockers, patients with a history of severe anaphylactic reaction to a variety of allergens [0m
[31mmay be more reactive to repeated challenge, either accidental, diagnostic, or therapeutic. Such patients may be unresponsive to the usual doses of epinephrine used to treat allergic reaction.         [0m
[31mSOURCE:LABETALOL label[0m


[31mCONTENT: LABETALOL: pregnancy: Pregnancy Teratogenic Effects: Pregnancy Category C: Teratogenic studies were performed with labetalol in rats and rabbits at oral doses up to approximately six and four[0m
[31mtimes the maximum recommended human dose [0m[1;31m([0m[31mMRHD[0m[1;31m)[0m[31m, respectively. No reproducible evidence of fetal malformations was observed. Increased fetal resorptions were seen in both species at doses [0m
[31mapproximating the MRHD. A teratology study performed with labetalol in rabbits at IV doses up to [0m[1;31m1.7[0m[31m times the MRHD revealed no evidence of drug related harm to the fetus. There are no adequate and [0m
[31mwell-controlled studies in pregnant women. Labetalol should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Nonteratogenic Effects: Hypotension, [0m
[31mbradycardia, hypoglycemia, and respiratory depression have been reported in infants of mothers who were treated with labetalol HCl for hypertension during pregnancy. LABETALOL: pregnancy: Oral [0m
[31madministration of labetalol to rats during late gestation through weaning at doses of two to four times the MRHD caused a decrease in neonatal survival.         [0m
[31mSOURCE:LABETALOL label[0m


[31mCONTENT: LABETALOL: adverse_reactions: Liver and Biliary System: Hepatic necrosis, hepatitis, cholestatic jaundice, elevated liver function tests. Musculoskeletal System: Muscle cramps, toxic [0m
[31mmyopathy. Respiratory System: Bronchospasm. Skin and Appendages: Rashes of various types, such as generalized maculopapular, lichenoid, urticarial, bullous lichen planus, psoriaform, and facial [0m
[31merythema; Peyronie's disease; reversible alopecia. Urinary System: Difficulty in micturition, including acute urinary bladder retention. Hypersensitivity: Rare reports of hypersensitivity [0m[1;31m([0m[31me.g., rash,[0m
[31murticaria, pruritus, angioedema, dyspnea[0m[1;31m)[0m[31m and anaphylactoid reactions. Following approval for marketing in the United Kingdom, a monitored release survey involving approximately [0m[1;31m6[0m[31m,[0m[1;31m800[0m[31m patients was [0m
[31mconducted for further safety and efficacy evaluation of this product. LABETALOL: adverse_reactions: Results of this survey indicate that the type, severity, and incidence of adverse effects were [0m
[31mcomparable to those cited above. Potential Adverse Effects: In addition, other adverse effects not listed above have been reported with other beta-adrenergic blocking agents. Central Nervous System: [0m
[31mReversible mental depression progressing to catatonia, an acute reversible syndrome characterized by disorientation for time and place, short-term memory loss, emotional lability, slightly clouded [0m
[31msensorium, and decreased performance on psychometrics. Cardiovascular: Intensification of A-V block [0m[1;31m([0m[31msee CONTRAINDICATIONS [0m[1;31m)[0m[31m. Allergic: Fever combined with aching and sore throat, laryngospasm, [0m
[31mrespiratory distress. Hematologic: Agranulocytosis, thrombocytopenic or nonthrombocytopenic purpura. Gastrointestinal: Mesenteric artery thrombosis, ischemic colitis. LABETALOL: adverse_reactions: The[0m
[31moculomucocutaneous syndrome associated with the beta-blocker practolol has not been reported with labetalol HCl. Clinical Laboratory Tests: There have been reversible increases of serum transaminases [0m
[31min [0m[1;31m4[0m[31m% of patients treated with labetalol HCl and tested and, more rarely, reversible increases in blood urea.         [0m
[31mSOURCE:LABETALOL label[0m


[31mCONTENT: LABETALOL: openfda: spl_id         [0m
[31mSOURCE:LABETALOL label[0m


[31mCONTENT: LABETALOL: precautions: Also, transient scalp tingling may occur, usually when treatment with labetalol hydrochloride tabletsis initiated [0m[1;31m([0m[31msee ADVERSE REACTIONS [0m[1;31m)[0m[31m. Laboratory Tests As with [0m
[31many new drug given over prolonged periods, laboratory parameters should be observed over regular intervals. In patients with concomitant illnesses, such as impaired renal function, appropriate tests [0m
[31mshould be done to monitor these conditions. Drug Interactions In one survey, [0m[1;31m2.3[0m[31m% of patients taking labetalol HCl in combination with tricyclic antidepressants experienced tremor, as compared to [0m[1;31m0.7[0m[31m%[0m
[31mreported to occur with labetalol HCl alone. The contribution of each of the treatments to this adverse reaction is unknown, but the possibility of a drug interaction cannot be excluded. LABETALOL: [0m
[31mprecautions: Drugs possessing beta-blocking properties can blunt the bronchodilator effect of beta-receptor agonist drugs in patients with bronchospasm; therefore, doses greater than the normal [0m
[31mantiasthmatic dose of beta-agonist bronchodilator drugs may be required. Cimetidine has been shown to increase the bioavailability of labetalol HCl. Since this could be explained either by enhanced [0m
[31mabsorption or by an alteration of hepatic metabolism of labetalol HCl, special care should be used in establishing the dose required for blood pressure control in such patients. Synergism has been [0m
[31mshown between halothane anesthesia and intravenously administered labetalol HCl. LABETALOL: precautions: During controlled hypotensive anesthesia using labetalol HCl in association with halothane, [0m
[31mhigh concentrations [0m[1;31m([0m[1;31m3[0m[31m% or above[0m[1;31m)[0m[31m of halothane should not be used because the degree of hypotension will be increased and because of the possibility of a large reduction in cardiac output and an [0m
[31mincrease in central venous pressure. The anesthesiologist should be informed when a patient is receiving labetalol HCl. Labetalol HCl blunts the reflex tachycardia produced by nitroglycerin without [0m
[31mpreventing its hypotensive effect. If labetalol HCl is used with nitroglycerin in patients with angina pectoris, additional antihypertensive effects may occur. Care should be taken if labetalol is [0m
[31mused concomitantly with calcium antagonists of the verapamil type. Both digitalis glycosides and beta-blockers slow atrioventricular conduction and decrease heart rate. LABETALOL: precautions: [0m
[31mcomitant use can increase the risk of bradycardia. Risk of Anaphylactic Reaction: While taking beta-blockers, patients with a history of severe anaphylactic reaction to a variety of allergens may be [0m
[31mmore reactive to repeated challenge, either accidental, diagnostic, or therapeutic. Such patients may be unresponsive to the usual doses of epinephrine used to treat allergic reaction. Drug & OR [0m
[31mLaboratory Test Interactions The presence of labetalol metabolites in the urine may result in falsely elevated levels of urinary catecholamines, metanephrine, normetanephrine, and vanillylmandelic [0m
[31macid when measured by fluorimetric or photometric methods. In screening patients suspected of having a pheochromocytoma and being treated with labetalol HCl, a specific method, such as a high [0m
[31mperformance liquid chromatographic assay with solid phase extraction [0m[1;31m([0m[31me.g. LABETALOL: precautions: J Chromatogr [0m[1;31m385:241[0m[31m,[0m[1;31m1987[0m[1;31m)[0m[31m should be employed in determining levels of catecholamines. Labetalol HCl [0m
[31mhas also been reported to produce a false-positive test for amphetamine when screening urine for the presence of drugs using the commercially available assay methods Toxi-Lab A Â® [0m[1;31m([0m[31mthin-layer [0m
[31mchromatographic assay[0m[1;31m)[0m[31m and Emit-d.a.u Â® [0m[1;31m([0m[31mradioenzymatic assay[0m[1;31m)[0m[31m. When patients being treated with labetalol have a positive urine test for amphetamine using these techniques, confirmation should be [0m
[31mmade by using more specific methods, such as a gas chromatographic-mass spectrometer technique. Carcinogenesis & Mutagenesis & Impairment Of Fertility Long-term oral dosing studies with labetalol HCl [0m
[31mfor [0m[1;31m18[0m[31m months in mice and for [0m[1;31m2[0m[31m years in rats showed no evidence of carcinogenesis.         [0m
[31mSOURCE:LABETALOL label[0m


[31mCONTENT: LABETALOL: clinical_pharmacology: Hemodynamic effects are variable, with small, nonsignificant changes in cardiac output seen in some studies but not others, and small decreases in total [0m
[31mperipheral resistance. Elevated plasma renins are reduced. Doses of labetalol HCl that controlled hypertension did not affect renal function in mildly to severely hypertensive patients with normal [0m
[31mrenal function. Due to the alpha [0m[1;31m1[0m[31m -receptor blocking activity of labetalol HCl, blood pressure is lowered more in the standing than in the supine position, and symptoms of postural hypotension [0m[1;31m([0m[1;31m2[0m[31m%[0m[1;31m)[0m[31m, [0m
[31mincluding rare instances of syncope, can occur. Following oral administration, when postural hypotension has occurred, it has been transient and is uncommon when the recommended starting dose and [0m
[31mtitration increments are closely followed [0m[1;31m([0m[31msee DOSAGE AND ADMINISTRATION [0m[1;31m)[0m[31m. Symptomatic postural hypotension is most likely to occur [0m[1;31m2[0m[31m to [0m[1;31m4[0m[31m hours after a dose, especially following the use of large [0m
[31minitial doses or upon large changes in dose. LABETALOL: clinical_pharmacology: The peak effects of single oral doses of labetalol HCl occur within [0m[1;31m2[0m[31m to [0m[1;31m4[0m[31m hours. The duration of effect depends upon [0m
[31mdose, lasting at least [0m[1;31m8[0m[31m hours following single oral doses of [0m[1;31m100[0m[31m mg and more than [0m[1;31m12[0m[31m hours following single oral doses of [0m[1;31m300[0m[31m mg. The maximum, steady-state blood pressure response upon oral, [0m
[31mtwice-a-day dosing occurs within [0m[1;31m24[0m[31m to [0m[1;31m72[0m[31m hours. The antihypertensive effect of labetalol has a linear correlation with the logarithm of labetalol plasma concentration, and there is also a linear [0m
[31mcorrelation between the reduction in exercise-induced tachycardia occurring at [0m[1;31m2[0m[31m hours after oral administration of labetalol HCl and the logarithm of the plasma concentration. About [0m[1;31m70[0m[31m% of the [0m
[31mmaximum beta-blocking effect is present for [0m[1;31m5[0m[31m hours after the administration of a single oral dose of [0m[1;31m400[0m[31m mg with suggestion that about [0m[1;31m40[0m[31m% remains at [0m[1;31m8[0m[31m hours. LABETALOL: clinical_pharmacology: The [0m
[31mantianginal efficacy of labetalol HCl has not been studied. In [0m[1;31m37[0m[31m patients with hypertension and coronary artery disease, labetalol HCl did not increase the incidence or severity of angina attacks. [0m
[31mExacerbation of angina and, in some cases, myocardial infarction and ventricular dysrhythmias have been reported after abrupt discontinuation of therapy with beta-adrenergic blocking agents in [0m
[31mpatients with coronary artery disease. Abrupt withdrawal of these agents in patients without coronary artery disease has resulted in transient symptoms, including tremulousness, sweating, palpitation,[0m
[31mheadache, and malaise. Several mechanisms have been proposed to explain these phenomena, among them increased sensitivity to catecholamines because of increased numbers of beta receptors. Although [0m
[31mbeta-adrenergic receptor blockade is useful in the treatment of angina and hypertension, there are also situations in which sympathetic stimulation is vital. LABETALOL: clinical_pharmacology: For [0m
[31mexample, in patients with severely damaged hearts, adequate ventricular function may depend on sympathetic drive. Beta-adrenergic blockade may worsen A-V block by preventing the necessary facilitating[0m
[31meffects of sympathetic activity on conduction. Beta [0m[1;31m2[0m[31m -adrenergic blockade results in passive bronchial constriction by interfering with endogenous adrenergic bronchodilator activity in patients [0m
[31msubject to bronchospasm, and it may also interfere with exogenous bronchodilators in such patients. Pharmacokinetics and Metabolism: Labetalol HCl is completely absorbed from the gastrointestinal [0m
[31mtract with peak plasma levels occurring [0m[1;31m1[0m[31m to [0m[1;31m2[0m[31m hours after oral administration. The relative bioavailability of labetalol HCl tablets compared to an oral solution is [0m[1;31m100[0m[31m%. The absolute bioavailability[0m
[1;31m([0m[31mfraction of drug reaching systemic circulation[0m[1;31m)[0m[31m of labetalol when compared to an IV infusion is [0m[1;31m25[0m[31m%; this is due to extensive [0m[31m"first-pass"[0m[31m metabolism. LABETALOL: clinical_pharmacology: Despite [0m
[31m"first-pass"[0m[31m metabolism, there is a linear relationship between oral doses of [0m[1;31m100[0m[31m to [0m[1;31m3[0m[31m,[0m[1;31m000[0m[31m mg and peak plasma levels. The absolute bioavailability of labetalol is increased when administered with [0m
[31mfood. The plasma half-life of labetalol following oral administration is about [0m[1;31m6[0m[31m to [0m[1;31m8[0m[31m hours. Steady-state plasma levels of labetalol during repetitive dosing are reached by about the third day of [0m
[31mdosing. In patients with decreased hepatic or renal function, the elimination half-life of labetalol is not altered; however, the relative bioavailability in hepatically impaired patients is increased[0m
[31mdue to decreased [0m[31m"first-pass"[0m[31m metabolism. The metabolism of labetalol is mainly through conjugation to glucuronide metabolites. These metabolites are present in plasma and are excreted in the urine [0m
[31mand, via the bile, into the feces.         [0m
[31mSOURCE:LABETALOL label[0m


[31mCONTENT: LABETALOL: laboratory_tests: Laboratory Tests As with any new drug given over prolonged periods, laboratory parameters should be observed over regular intervals. In patients with concomitant [0m
[31millnesses, such as impaired renal function, appropriate tests should be done to monitor these conditions.         [0m
[31mSOURCE:LABETALOL label[0m

 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m<[0m[1;32mDONE[0m[1;32m>[0m[32m DO-NOT-KNOW[0m
 [1m([0morchestrator-hospitalization-LABETALOL[1m)[0m [31m FDAHandler [0m [1;34mEntity.USER[0m[1m([0mFDAHandler[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDO-NOT-KNOW[0m
 [1m([0morchestrator-hospitalization-LABETALOL[1m)[0m [31m Critic [0m [1;34mEntity.USER[0m[1m([0m    Critic[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
*[1m([0morchestrator-hospitalization-LABETALOL[1m)[0m [37m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDO-NOT-KNOW[0m
 [1m([0morchestrator-hospitalization-LABETALOL[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-hospitalization-LABETALOL[1m)[0m [31m Entity.AGENT [0m
*[1m([0morchestrator-hospitalization-LABETALOL[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m<[0m[1;32mDONE[0m[1;32m>[0m[32m DO-NOT-KNOW[0m

[32mThe question asked whether labetalol increases or decreases the risk of hospitalization. The FDA label data does not specify any information regarding labetalol's effect on the risk of [0m
[32mhospitalization. Therefore, it is not possible to determine from the FDA label whether labetalol has an impact on hospitalization risk. Without specific data, we cannot establish a causal relationship[0m
[32mor assess the degree of risk associated with labetalol in the context of hospitalization.[0m
